These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20484204)

  • 1. Cellular immunotherapy licensed for advanced prostate cancer.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
    [No Abstract]   [Full Text] [Related]  

  • 2. New treatments for metastic prostate cancer.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy: a new option for advanced prostate cancer.
    Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869
    [No Abstract]   [Full Text] [Related]  

  • 5. Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
    Goodman AJ
    J Contemp Health Law Policy; 2008; 25(1):107-41. PubMed ID: 19137749
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy: An immune one-two punch.
    Bourzac K
    Nature; 2015 Dec; 528(7582):S134-6. PubMed ID: 26672788
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Landmark approval for Dendreon's cancer vaccine.
    DeFrancesco L
    Nat Biotechnol; 2010 Jun; 28(6):531-2. PubMed ID: 20531312
    [No Abstract]   [Full Text] [Related]  

  • 9. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
    Chambers JD; Neumann PJ
    N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concerns about Provenge simmer as CMS ponders coverage.
    Goozner M
    J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches.
    Arlen PM
    Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer vaccines.
    Michael A; Relph K; Annels N; Pandha H
    Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells and T cells in immunotherapy.
    O'Neill DW
    J Drugs Dermatol; 2010 Nov; 9(11):1383-92. PubMed ID: 21061761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provenge: combating prostate cancer with a vengeance?
    Schwaab T; Pili R
    Expert Rev Vaccines; 2011 Aug; 10(8):1113-4. PubMed ID: 21854304
    [No Abstract]   [Full Text] [Related]  

  • 17. Sipuleucel-T shows partial advantage in prostate cancer.
    Gould P
    Lancet Oncol; 2006 Sep; 7(9):710. PubMed ID: 16981300
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).
    Harzstark AL; Small EJ
    Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for prostate cancer: walk, don't run.
    Drake CG
    J Clin Oncol; 2009 Sep; 27(25):4035-7. PubMed ID: 19635998
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival.
    Peskin SR
    Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.